Deal announcement

Krzewinski+Partners successfully assisted Spinovit in its first financing round, supported by Vives, W.I.N.G and B2Start.

Spinovit is a spin off from UCLouvain and proposes a robust biomarker of the endothelial dysfunction for the detection of the early stages of any cardiovascular disease.

Deal team: Christophe Krzewinski - Samuel Darcheville

Précédent
Précédent

Deal announcement

Suivant
Suivant

Deal announcement